Detalhe da pesquisa
1.
Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
HIV Clin Trials
; 16(1): 43-8, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25777189
2.
Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.
J Antimicrob Chemother
; 63(1): 178-83, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18952618
3.
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
PLoS One
; 14(9): e0221567, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31550267
4.
Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.
PLoS One
; 11(2): e0148924, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26872331